@article{bc170f25b4e346dfb495588ed8c499e5,
title = "Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)",
author = "Thilagar, {Bright P.} and Ghosh, {Aditya K.} and Jerome Nguyen and Theiler, {Regan N.} and Wick, {Myra J.} and Hurt, {Ryan T.} and Razonable, {Raymund R.} and Ravindra Ganesh",
note = "Funding Information: Financial Disclosure Ryan T. Hurt is a consultant for Nestle Nutrition. Raymund R. Razonable is principal investigator of clinical trials on COVID-19 treatment funded by Gilead (remdesivir), Regeneron (sarilumab, casirivimab-imdevimab), Roche (tocilizumab), and research on Monoclonal Antibody Therapy funded by the Mayo Clinic. They have been on the data safety monitoring board for a Novartis clinical trial. They disclosed that bamlanivimab, bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab are all investigational products authorized for emergency use EUA by the U.S. FDA. The other authors did not report any potential conflicts of interest. ",
year = "2022",
month = apr,
day = "1",
doi = "10.1097/AOG.0000000000004700",
language = "English (US)",
volume = "139",
pages = "616--618",
journal = "Obstetrics and gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "4",
}